Dr. Alan F. Joslyn Ph.D. is President, Chief Executive Officer, Director of the Company. Prior to joining the Company, Dr. Joslyn was a partner in Lazarus Pharmaceuticals. Prior to that he served as the Chief Executive Officer and director of several privately held companies including Edusa Pharmaceuticals and Sentinella Pharmaceuticals and prior to that he was the Senior Vice-president Research and Development of Penwest Pharmaceuticals Company and held senior positions with Johnson & Johnson. Dr. Joslyn received his bachelor of sciences degree in biology and medical chemistry from State University of New York at Buffalo in 1981, later earning doctorate in biochemical pharmacology from State University of New York at Buffalo in 1986.
Alan Joslyn is 59, he's been the President, Chief Executive Officer és Director of Oragenics Inc since 2016. There are 6 older and 2 younger executives at Oragenics Inc. The oldest executive at Oragenics Inc is Dr. Frederick W. Telling Ph.D., 69, who is the Exec. Chairman.
Alan's mailing address filed with the SEC is 4902 EISENHOWER BOULEVARD, , TAMPA, FL, 33634.
Over the last 12 years, insiders at Oragenics Inc have traded over $5,827,684 worth of Oragenics Inc stock and bought 8,095,027 units worth $13,189,855 . The most active insiders traders include Randal Jintrexon Corp Kirk, Joseph Hernandez és Robert C Koski. On average, Oragenics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $151,398. The most recent stock trade was executed by Fred Telling on 30 November 2023, trading 3,500 units of OGEN stock currently worth $12,495.
oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies. offerings are based on the probiora3 technology and brands include evoraplus™ is a new, one-of-a-kind probiotic mint that naturally supports gum and tooth health while freshening breath and whitening teeth. oragenics has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, in diagnostics, and in oral health.
Oragenics Inc executives and other stock owners filed with the SEC include: